Dr. Jason Martin Leibowitz, MD

Dr. Leibowitz practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Leibowitz's NPI, 1124184072, was assigned on December 28, 2006. Dr. Leibowitz graduated from New York University School of Medicine in 2005. Dr. Leibowitz holds Florida license ME106030.

Dr. Leibowitz's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Leibowitz's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Leibowitz to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leibowitz practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Leibowitz's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Leibowitz is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Leibowitz's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists larynx and vocal cord disease and thyroid surgery among the conditions Dr. Leibowitz treats.

CMS data shows 926 Medicare services from Dr. Leibowitz across 16 procedure codes in 2024, for 306 Medicare patients. Medicare paid $106,240 for them.

CMS counts 306 Medicare patients who saw Dr. Leibowitz in 2024. The largest group is 65 to 74, with 141 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leibowitz's median patient age at 72, with 39% women.

In 2024, Dr. Leibowitz wrote 315 Medicare Part D claims for 116 patients. 81% of them were for generic drugs. CMS names the drug for 185 of them, across 8 drugs with 11 or more claims each, at $1,607 in total drug cost. In 2023, CMS named 166 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Leibowitz for performance year 2024, reported as part of a group. Dr. Leibowitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leibowitz as offering telehealth. CMS counts 13 procedures of melanoma (skin cancer) excision by Dr. Leibowitz, more than 67% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 31 papers to Dr. Leibowitz, published from 2011 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Plastic Surgery Procedures. Dr. Leibowitz has published most often in Head Neck. Dr. Leibowitz's most frequent co-authors are Zoukaa B. Sargi, MD, Francisco J. Civantos, MD and Donald T. Weed, MD.

CMS Open Payments shows 56 general payments to Dr. Leibowitz from 8 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 59% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $8,369.

Dmand AI lists 5 awards for Dr. Leibowitz, most recently CMS Stage 1 EHR in 2013.

Dr. Leibowitz graduated from New York University School of Medicine in 2005. Dr. Leibowitz is a member of NHS and ACS.

Dr. Leibowitz is in network with 11 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.